Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 10 months ago

Anticoagulation
Timing of SGLT2 Inhibitors in Heart Failure
Author(s): Moritake Iguchi , Hiromichi Wada , Felipe Martínez , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 9 months ago

Anticoagulation
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 1 year ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
Luca Testa
Research Area(s) / Expertise: Job title: Interventional Cardiologist
Dr Testa is an Interventional Cardiologist working at the IRCCS Policinico San Donato in San Donato, Milan, Italy. He is Head of the Coronary Revascularization Unit as well as of the Clinical Research Unit. His areas of research range from platelet aggregation, intracoronary imaging and physiology related to structural heart disease, particularly the TAVI. He is also particularly… View more
Factor XI Inhibition and AF
Author(s): Bianca Rocca , Hugo ten Cate Added: 1 month ago

Anticoagulation

Electrophysiology & Arrhythmia
Prognostic Utility of the ABCD-GENE Score in Asian ACS Patients
Author(s): Cheng Keat Tan , David Bin-Chia Wu , Seh Yi Joseph Tan , et al Added: 1 year ago

Anticoagulation

MI/ACS
Research Area(s) / Expertise: Job title: Adjunct Professor of Pharmacology
ACC 25: The Phase 3 REVERSE-IT Trial
Author(s): Deepak L Bhatt Added: 1 month ago
ACC 2025 - Phase three results of the use of bentracimab in patients who need urgent ticagrelor reversal show significantly restored platelet function as measured by percent inhibition of P2Y12 Reaction Unit (PRU).Dr Deepak L Bhatt (Mount Sinai Fuster Heart Hospital, New York, US) joins us onsite at ACC 2025 to discuss phase three results from the multi-center, open-label, single-arm REVERSE-IT… View more

Anticoagulation
Research Area(s) / Expertise: Job title: Aggregate Professor of Internal Medicine